Skip to main content
spacbrain

Helix Acquisition Corp

HLXA · Nasdaq

Trust settledMoonLake Immunotherapeutics · Finished

NO ACTION REQUIRED

Nothing left to do

The purchase completed and the shares became shares in the company it bought. There is no deadline left to miss.

Cash at settlement

no closing figure

No cash-per-share figure was filed for this vehicle before it finished.

Last close

no quote on file

Daily close

Nothing left to claim

this vehicle finished

There is nothing to hand back: holders who wanted cash elected it at the vote, and the rest became shares in the buyer.

Read what happened to the cash

The floor

Trust settled

This SPAC has finished — its trust was paid out or used to close the deal, so there is nothing left to redeem

Read the reasoning behind this verdict

No price history on file yet — daily closes accumulate from the market data feed.

Trust settled · There is no line to draw here. This vehicle has finished: the cash was paid back or spent closing the deal, so the last filed figure describes an account that no longer exists and would be a floor under nothing.

SpacBrain’s read

Trust settled

The deal closed — SPAC shares became the target's shares, so there is no trust left to redeem (nobody missed a window; holders who wanted cash elected it at the vote).

In plain terms

What it is
A SPAC from Helix Acquisition (Obradovic Nebojsa), listed on Nasdaq in October 2020.
What it's doing now
It agreed to buy MoonLake Immunotherapeutics. That purchase completed, and it stopped being a SPAC — the shares became shares in the business it bought.
What you should know
This SPAC has finished. The purchase completed, and the shares became shares in the company it bought — anyone who wanted the cash instead asked for it at the vote, so there is no cash left here to claim and no deadline left to miss.

At a glance

Where it stands
Closed (deSPAC)
The business it bought
MoonLake Immunotherapeutics
Industry
the deal record does not name the target's industry yet
Deal value
not stated in the filings we hold
Price vs cash at settlement
no live price on file
Cash in trust when it settled
not yet extracted into a snapshot — the filings below may state it
the last trust total filed while this was still a SPAC — the account has since been paid out or used to close the deal
IPO
21 October 2020
size not on file
Headquarters
DORFSTRASSE 29, ZUG, V8, 6300
registered in the Cayman Islands
Lead underwriter
not extracted from the prospectus yet
Key officers
Reich Kristian (Chief Scientific Officer) · Santos da Silva Jorge (Chief Executive Officer) · Bodenstedt Matthias (Chief Financial Officer)
Listed securities
HLXA common
Cash held per sharenot filed for this window

This vehicle has finished, so there is no window to file a cash-per-share figure for and none will follow. No estimate is shown in its place.

Next date that mattersno dated event on file

Nothing dated is on file. That is an absence in the record, not a statement that nothing is coming.

Yield to redemption

Nothing left to redeem — no yield to compute.

This SPAC has finished — its trust was paid back or used to close the deal, so there is nothing left to redeem and no yield to compute. A yield to redemption is a claim that you can hand these shares back for the trust cash. That account is closed, so this page will not print a number here.

What happened to the cash

The reasoning behind the verdict above, in the order the filings establish it.

  1. The deal closed — SPAC shares became the target's shares, so there is no trust left to redeem (nobody missed a window; holders who wanted cash elected it at the vote).

What has happened, and what is coming

2 dated milestones

Every dated step from the day it listed to the next date you may have to act on. Where you have to do something, the day your broker needs the instruction is marked too.

  1. 21 October 2020IPOpassed

    IPO size not on file

  2. 31 March 2022Deal votepassed0001213900-22-010753opens on sec.gov in a new tab

Presentations

archived in full

Every investor deck this SPAC has filed, kept slide by slide, with the SEC original beside it.

Investor presentations · archived in full

The deal

terms as filed

What it is buying, on what terms, and how much of the combined company new shares take from you.

The score

deterministic, from filed fields

HLXA is not in the scored universe, so no score is shown. A withheld score is a fact about the record, not a verdict about the company.

Asymmetric return scoreNeither a price nor a cash-per-share figure is on file for this vehicle, and the score is a ratio between the two. Nothing is estimated to fill the gap.

The score is only published for names that carry both a price and a filed cash-per-share figure — 294 of the tracked fleet today. The rest keep an empty dial rather than a modelled one, and fill in by themselves as the fields land.

See the names that are scored, and how

The company

from SEC filings
Read the full profile

Helix Acquisition Corp was a blank-check company whose common stock traded on the Nasdaq Stock Market under the ticker HLXA. The company priced its initial public offering on October 21, 2020, under SEC file number 333-249197, pursuant to an S-1 registration statement (accession 0001213900-20-029401) and a 424B4 prospectus (accession 0001213900-20-032599) in which the registrant described itself as a blank-check entity. Its SEC SIC industry code was 2834 (Pharmaceutical Preparations), and its SEC CIK was 0001821586. The company completed a business combination and no longer files as a blank-check vehicle, with the change in shell company status reported on an 8-K filed April 11, 2022 (accession 0001213900-22-019217). EDGAR now files this CIK under the name MoonLake Immunotherapeutics.

Material findings

from the full read of every filing

Every document this company files gets read whole — body and exhibits. These are the ones the read flagged as material, newest first, each citing its filing.

  • 8-K10 August 20260001213900-26-086939opens on sec.gov in a new tab

    The percentages are absolute response rates in one treatment arm with no placebo comparison disclosed — the placebo-controlled comparison is still blinded — so the size of the treatment effect cannot be read from this release. The lead indication's BLA has not yet been submitted.

  • 10-Q10 August 20260001821586-26-000010opens on sec.gov in a new tab

    The company funded a $131.5 million half-year loss and still grew cash, through roughly $255 million of additional paid-in capital and $25 million of incremental debt. Operating spend is running at about $62 million a quarter.

  • 8-K15 July 20260001213900-26-078031opens on sec.gov in a new tab

    Full exercise of the greenshoe means the offering was oversubscribed at the pricing level, so demand rather than distress drove this raise — a distinction that matters at a clinical-stage de-SPAC where most equity issuance is defensive. The $30.0 million of extra gross proceeds extends the runway ahead of clinical milestones, at the cost of 1,500,000 more shares plus the pre-funded warrants issued in the base deal, which convert on payment of a nominal exercise price and should be counted as outstanding for dilution purposes.

  • DEFM14A14 February 20220001213900-22-007163opens on sec.gov in a new tab

    MoonLake stays the operating company: its existing securityholders keep their MoonLake equity and receive non-economic voting shares in Helix, the BVF Shareholders alone assign their MoonLake Common Shares for Class A Ordinary Shares, and Helix takes a controlling interest by making the Cash Contribution. The Exchange Ratio as printed is malformed — it is defined as the quotient obtained by dividing (a) 360,000,000 by (b) MoonLake's fully diluted shares before the Closing by (c) 10, a single quotient with two divisors, so the ratio cannot be evaluated from this sentence alone.

  • PREM14A29 October 20210001213900-21-055441opens on sec.gov in a new tab

    The Rule 0-11 value of $216,288,872, on which a fee of $20,049.98 was paid, is not a valuation of MoonLake: it is the cash Helix expects to contribute — $115,038,872 held in trust as of June 30, 2021 assuming no public shareholder redeems, less $13,750,000 of permitted transaction expenses, plus $115,000,000 expected from a private placement closing immediately before the combination. Most MoonLake holders keep their MoonLake equity and take only non-economic voting shares in Helix; only the BVF Shareholders assign their shares for Class A Ordinary Shares.

Filings

live EDGAR feed

Everything this company has filed with the SEC recently, newest first, each with a plain summary of what changed and why it matters.

Show the other 10 filings
  • 8-K10 August 20260001213900-26-086939opens on sec.gov in a new tab

    What changed: Exhibit 99.1 to an 8-K of MoonLake Immunotherapeutics (Nasdaq: MLTX): the August 10, 2026 press release reporting Week 16 topline results from the Phase 3 IZAR-1 trial of sonelokimab in biologic-naïve adults with active psoriatic arthritis, together with Q2 2026 financial results. Why it matters: The percentages are absolute response rates in one treatment arm with no placebo comparison disclosed — the placebo-controlled comparison is still blinded — so the size of the treatment effect cannot be read from this release. The lead indication's BLA has not yet been submitted.

  • 10-Q10 August 20260001821586-26-000010opens on sec.gov in a new tab

    What changed: Q2 2026 10-Q of MoonLake Immunotherapeutics (Nasdaq: MLTX). Cash and equivalents rose to $477,905 thousand at June 30, 2026 from $334,517 thousand at December 31, 2025, with short-term marketable debt securities of $59,125 thousand, taking total assets to $573,947 thousand from $424,433 thousand. Long-term debt rose to $99,514 thousand from $74,100 thousand and total liabilities to $145,752 thousand. Why it matters: The company funded a $131.5 million half-year loss and still grew cash, through roughly $255 million of additional paid-in capital and $25 million of incremental debt. Operating spend is running at about $62 million a quarter.

  • 429 July 20260001213900-26-082804opens on sec.gov in a new tab
  • 423 July 20260001213900-26-080869opens on sec.gov in a new tab
  • 421 July 20260001213900-26-080133opens on sec.gov in a new tab
  • 420 July 20260001213900-26-079376opens on sec.gov in a new tab
  • 8-K15 July 20260001213900-26-078031opens on sec.gov in a new tab

    What changed: MoonLake Immunotherapeutics, the Helix Acquisition Corp successor, reported that on July 10, 2026 the underwriters of its previously announced public offering of Class A ordinary shares — and, for certain investors, pre-funded warrants in lieu of shares — exercised in full their option to purchase an additional 1,500,000 ordinary shares. The exercise produced additional gross proceeds of $30.0 million before underwriting discounts, commissions and offering expenses, and the closing of the issuance and sale of the option shares occurred on July 14, 2026. Why it matters: Full exercise of the greenshoe means the offering was oversubscribed at the pricing level, so demand rather than distress drove this raise — a distinction that matters at a clinical-stage de-SPAC where most equity issuance is defensive. The $30.0 million of extra gross proceeds extends the runway ahead of clinical milestones, at the cost of 1,500,000 more shares plus the pre-funded warrants issued in the base deal, which convert on payment of a nominal exercise price and should be counted as outstanding for dilution purposes.

  • 14415 July 20260001969223-26-000787opens on sec.gov in a new tab
  • 413 July 20260001213900-26-077564opens on sec.gov in a new tab
  • 42 July 20260001213900-26-074964opens on sec.gov in a new tab

The record

The reference detail — how the shares were structured at listing, how thinly they trade, and where the company is registered.

Show the reference detail

Unit structure

Cash in trust at IPOnot extracted from the prospectus

from 424B3 0001628280-23-023592

Trading & liquidity

Average daily volume (20d)no volume reported on the bars we hold
Average daily $ volumeneeds both volume and a live price
Range over the bars heldnot enough price history
Total cash in trustthe trust total is not in the last XBRL stamp

Company profile

Industry (SIC)Pharmaceutical Preparations (2834)
Registered inthe Cayman Islands
Exchange · CIKNasdaq · 0001821586

All filings on EDGARopens on sec.gov in a new tab

Directors & officers

Institutional holders

from SC 13G/13D

Funds that have declared a stake above 5%. Heavy ownership by arbitrage funds usually means heavy cash-outs at the next vote.

Show the declared stakes

10 filers with a stake on file · 0 re-affirmed in the last 12 months. A stake with no amendment since is the filer’s last word on it, not proof it is still held — and percentages filed in different years are percentages of different floats, because this vehicle’s share count collapses at every redemption.

One line per filer, not per reporting person: a joint schedule names the management company, its funds and often the individual who controls them, and all of them report the same shares. Click a name for that filer’s whole footprint across every SPAC it has declared a stake in.

News

company wires and the financial press

Reporting we have matched to this ticker. Headlines belong to the outlets that wrote them.

Show the headlines

Sources on file

harvested pages, kept in full

Every public page we have read about this company, stored in full so a source can never go missing.

Show the sources

38 full SEC filing texts archived — searchable, never lost.

In plain English

tap a term to open it

Every piece of jargon this page could have used, and what it actually means.

Open the plain-English guide
No floor / floorlessthe cash guarantee is gone — the price is unprotected

A SPAC's downside protection is not the cash in trust; it is your right to demand that cash. Once the redemption window closes, the cash stays with the company and the share can trade anywhere.

Redemption deadlinethe last day to hand shares back for cash

Set by the filing that calls the meeting. Tender after it and the company is under no obligation to pay you the trust value.

Broker action datethe day your broker needs the instruction — earlier than the official date

Brokers batch redemption instructions to the transfer agent, so the practical cutoff is roughly two business days before the published deadline. This is the date that actually costs people the floor.

Cash in trust / trust per sharethe cash the company is holding for each public share

Filed quarterly in the 10-Q's XBRL. It earns interest between filings, so the figure on a given day is slightly higher than the last filed one — where we show that we label it an estimate.

Trust discountbuying below the cash held for you

Only meaningful while a redemption right exists. On a floorless name the same arithmetic is not a discount, it is the market pricing distress, and this product will not call it a yield.

Dilutionhow much of the company new shares take from you

Sponsor promote, PIPE shares, warrants and rights all issue stock that did not pay $10 for it. The headline deal value is before that; the effective value is after.

Pro-forma equitywhat the company is valued at once the deal closes

The combined company's equity value assuming the announced terms and the redemptions that have actually happened.

ARShow much upside you get per unit of downside

SpacBrain's asymmetric-return score. It is deterministic — the same inputs always produce the same number — and it is capped, not zeroed, when the floor is gone.

De-SPACthe day the SPAC becomes the real company

The shares stop being a claim on a pot of cash and start being equity in an operating business. Roughly 80% of recent de-SPACs traded below $10 within a year.

Outside datethe contractual long-stop for closing the deal

A deadline between the SPAC and its target, not between the SPAC and you. It confers no right to cash, which is exactly why it must never be counted as a redemption window.

Accession numberthe SEC's unique id for one filing

Every figure on this page carries the accession of the filing that states it, so you can open the primary document rather than trust us.

Accreted NAV (estimate)the last filed cash figure, plus the interest it should have earned since

A model, not a filing: last filed value compounded at the 3-month T-bill for the days elapsed. Always shown in italic with the word estimate, and never printed beside a filed number without it.

Ask the brain

from its filings
Data provenance & audit trail4 internal entries

Written by SpacBrain’s data agents whenever a figure is captured, corrected or flagged, and kept verbatim so every number on this page can be traced back to the filing that states it. This is a running log, not the current record: an early entry may be superseded by a later correction — the panels above always hold the current values.

HLXA — company record
UNIVERSE-IPO-INDEX2026-08-17

admitted from EDGAR's QUARTERLY FORM INDEX, walked without any SIC filter. The SIC 6770 census could not reach this registrant: EDGAR reassigns a shell's SIC the day it stops being one, and this CIK now files under 2834 (Pharmaceutical Preparations). The screen found it by filing SHAPE instead — S-1 2020-10-01 → 8-A12B 2020-10-19 → 424B4 2020-10-21 — which nothing rewrites. Admission rule: src/lib/universe-admit.ts. SIC 2834 + self-described blank check in 424B4 0001213900-20-032599; 424B 0001213900-20-032599 priced 2020-10-21 under S-1 0001213900-20-029401 (file 333-249197, an offering for cash); common ticker HLXA off 10-K 0001213900-22-008253 (2022-02-17); lifecycle ACTIVE. The pricing prospectus was filed under SEC file number 333-249197, which belongs to S-1 0001213900-20-029401 (2020-10-01) — a registration of shares sold for CASH, which is what makes it an IPO rather than merger consideration. Blank-check status from the registrant's own first-person sentence in that prospectus (EDGAR full-text search, 424B4 2020-10-21). Ending PROVEN, not inferred: CLOSED per 8-K 0001213900-22-019217 (2022-04-11) — 8-K item 5.06 "Change in Shell Company Status" (EDGAR item index, items: 1.01,2.01,3.02,3.03,5.01,5.02,5.03,5.05,5.06,7.01,9.01). EDGAR now files this CIK as "MoonLake Immunotherapeutics" — the SPAC's own name is kept here and the successor is the target. ipoSizeM and deadline left NULL: gross-proceeds prose conflates the over-allotment with the offering, and a charter deadline belonging to a vehicle that has ended is a date nobody can act on. ipoDate is the 424B pricing date.

SPONSOR-ID2026-08-14

sponsor "Helix Holdings LLC" (SEC CIK 0001821548) sourced from Form 3 reportingOwner (10% owner) acc 0001213900-20-032151.

Deal — MoonLake Immunotherapeutics
UNTAGGED

[CLOSED-RENAME] EDGAR CIK 0001821586 records "Helix Acquisition Corp" ending 2022-03-31; the registrant continues as "MoonLake Immunotherapeutics". The rename is the SEC's own record of what the vehicle became, keyed by CIK. Closed 2022-03-31. No deal value is set — a rename says what was acquired, never for how much. No date column is set: Deal has announcedAt, voteDate and expectedCloseAt and nowhere to record an actual close, so the SEC's date is kept here until that column exists. [DEAL-STRUCTURE-MINED] minCashM=150 from primary filings (0001213900-22-007163).

PROFILE-STUB2026-08-25

entity created from the filed target name; no About paragraph on file, so every other field awaits a sourced read

Back to the screenerVault note